Compare Intel Corp (INTC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Neurocrine Biosciences Inc — how do they compare? Intel Corp trades at $108.8 (market cap $566.04B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Intel Corp is far larger — about 39.4× Neurocrine Biosciences Inc's market cap, and Intel Corp pays a 2.24% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Neurocrine Biosciences Inc for 23 Days on average.
| INTC | NBIX | |
|---|---|---|
Market Cap | $566.04B | $14.36B |
Volume | 118,475,837 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $140.94 | $185.50 |
52-Week Low | $33.62 | $123.10 |
Typical Hold Time | 116 Days | 23 Days |
Enterprise Value | $586.85B | $14.37B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $113.12, up 0.55% today, with a bullish technical signal and recent earnings beats. The stock has surged over 220% in 2026, driven by AI momentum and foundry growth, though fundamentals show negative net income margins and elevated valuations. Cash flow improved in 2025, but revenue remains below 2022 peaks amid intense competition.
Outlook hinges on foundry turnaround execution; upside exists if Intel captures external customers for advanced nodes, but high debt and margin pressures pose risks. Analyst consensus is cautious with a $111.72 target, slightly below current price, reflecting skepticism on sustainability despite recent gains.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
